UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 28, 2018
ALBIREO PHARMA, INC.
(Exact name of registrant as specified in its charter)
Delaware |
| 001-33451 |
| 90-0136863 |
10 Post Office Square, Suite 502 South |
| 02109 |
(857) 254-5555
Registrant’s telephone number, including area code
Not applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On February 28, 2018, Peter A. Zorn, Esq. stepped down from his positions as Chief Corporate Officer, General Counsel and Secretary of Albireo Pharma, Inc. (“Albireo”), effective April 1, 2018, to pursue other career opportunities.
Mr. Zorn has executed an agreement with Albireo that includes a release, waiver and other customary provisions and will receive the post-separation pay and continuation of health insurance benefits provided for under his employment agreement with Albireo effective July 11, 2015. In addition, the agreement provides for acceleration of vesting for unvested stock options granted to Mr. Zorn prior to April 1, 2017, through December 31, 2018.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ALBIREO PHARMA, INC. |
|
|
Date: March 6, 2018 | /s/ Ronald H.W. Cooper |
| Ronald H.W. Cooper |
| President and Chief Executive Officer |